Understanding the Berotralstat Synthetic Route Patent
The patent for the synthetic route of berotralstat, a medication used to treat hereditary angioedema (HAE), is a key piece of intellectual property for BioCryst Pharmaceuticals [1]. This patent protects the specific chemical process used to manufacture the drug, which is crucial for its commercial viability and exclusivity [2].
Why are companies interested in the Berotralstat synthesis?
The details of berotralstat's synthesis are of significant interest to generic drug manufacturers and competitors [3]. If the patent protecting the manufacturing process expires or is successfully challenged, it could pave the way for the production of generic versions of berotralstat [2]. This would likely lead to lower drug prices and increased market competition [4]. Information on drug patents, including those related to synthesis routes, is often tracked by resources like DrugPatentWatch.com [5].
When does Berotralstat's synthesis patent expire?
The expiration date of a patent for a synthetic route can differ from the patent covering the drug itself. Companies often seek patents for various aspects of a drug, including its composition, formulation, method of use, and manufacturing process [2]. Determining the precise expiration of the berotralstat synthetic route patent requires consulting specific patent filings and databases [5].
What are the implications of the berotralstat synthesis patent for BioCryst?
For BioCryst Pharmaceuticals, the patent for berotralstat's synthetic route provides a period of market exclusivity, allowing them to recoup research and development costs and generate revenue without direct competition from manufacturers using the same patented process [1][2]. Challenges to this patent, whether through litigation or by demonstrating non-infringement, could significantly impact BioCryst's market position and revenue streams [3].
How does berotralstat work and what is it used for?
Berotralstat, marketed as Orladeyo, is a plasma kallikrein inhibitor [6]. It works by blocking the action of plasma kallikrein, an enzyme that plays a role in the swelling attacks characteristic of HAE [6][7]. By inhibiting this enzyme, berotralstat reduces the frequency and severity of HAE attacks [7].
What are the alternatives to berotralstat for HAE?
Patients with HAE have several treatment options besides berotralstat. These include acute attack treatments and prophylactic (preventative) therapies [8]. Acute treatments are administered during an HAE attack and include medications like C1 esterase inhibitor (human) and ecallantide [8]. Prophylactic treatments are taken regularly to prevent attacks and include self-administered injections such as C1 esterase inhibitor (human), lanadelumab, and subcutaneous C1 esterase inhibitor (human) [8].
Sources:
[1] BioCryst Pharmaceuticals Investor Relations
[2] U.S. Food & Drug Administration (FDA) Orange Book
[3] Generic Pharmaceutical Association (GPhA)
[4] Congressional Budget Office (CBO) reports on drug pricing
[5] https://drugpatentwatch.com/
[6] Orladeyo (berotralstat) prescribing information
[7] National Organization for Rare Disorders (NORD) - Hereditary Angioedema
[8] American Academy of Allergy, Asthma & Immunology (AAAAI) - Hereditary Angioedema